Extended Data Fig. 1: Pcif1 KO mice exhibit normal phenotypes and retarded tumor growth.
a, A schematic representation of the process for creating whole-body Pcif1 KO mice through the crossbreeding of Pcif1flox/flox mice with CAG-Cre transgenic mice. b, The mRNA level of Pcif1 was analyzed by real-time PCR in Pcif1 KO or WT mice. n = 4 mice/each group. c, The protein level in tissues of both WT (n = 3) and Pcif1 KO (n = 4) mice. d-f, The representative images show the body size (d), tissue weight/body weight ratio (e) (n = 6), and body weight (f) (n = 14) of WT or Pcif1 KO mice. g,h, The assessments of liver function (g), and routine blood tests (h) between Pcif1 KO mice and their WT littermates. n = 8 mice/each group. i-k, Flow cytometry analysis of thymocytes, peripheral T cells isolated from spleen and lymph nodes of Pcif1 KO and WT mice. i,j, Percentages of CD4+ and CD8+ T cells in spleen and lymph nodes of Pcif1 KO and WT mice. k, Percentages of CD4−CD8− double-negative (DN), CD4+CD8+ double-positive (DP), CD4+ single-positive (CD4SP) and CD8+ single-positive (CD8SP) cells out of the total number of thymocytes from Pcif1 KO and WT mice. n = 4 mice/each group. l-n, Tumor growth of LLC (l), B16-F10 (m) or MC38 cells (n) was assessed in WT or Pcif1 KO mice. Tumor volumes of mice were measured every two days. Each symbol represents an individual mouse. Two-tailed unpaired Student’s t-test (b, e-k) was performed. Data are shown as the mean ± SEM.
